Webinar
/
February 3, 2024

A Patient-First Perspective on Digital Therapeutics: A Presentation from DTx West

Employees describe the life-changing impacts of Sleepio and Daylight

Originally presented at the DTx West 2021 Conference on February 24th 2021.

Join Big Health’s CEO and Co-founder Peter Hames as he speaks with two employees — Tim and David — who have greatly improved their sleep and mental health with Sleepio and Daylight.

David describes the impact Daylight had on his life as: “to be able to take control back, do more with kids and be available to them. To be in a good mood and not be this ‘grumpy dad’. It was priceless.”

If you don’t have time to watch the full video you can read about Tim and David’s stories in our recent blog.

Copy Link

Watch the replay

Here’s our latest

Benefits to Break the Stigma: Addressing caregivers with mental health support

60% of US adults suffer from mental health challenges in silence, due to stigma and other barriers to proper support & care and many of these silent sufferers are caregivers. 1 in 5 of us is caring for a loved one at any given time, and 72% of caregivers report symptoms of clinical depression. Benefits...

Webinar
Conversations with Colin: Exploring the state of mental health

Part 1: The impact of the mental health crisis

Webinar
Conversations with Colin: How digital therapeutics fit into the standard of care in mental health

Professor Colin Espie wears many hats: Co-Founder of Big Health, Oxford University Professor of Sleep Medicine, and world-renowned clinical psychologist. With over 40 years of experience and upwards of 300 published clinical papers, Professor Espie’s superpower is taking complex mental health topics and distilling them in an engaging, empathetic storytelling-like style that anyone can understand....

Webinar

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. https://www.nice.org.uk/advice/mib129.5. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023